Coronavirus | Covid-19 | Peer Reviewed Journals Articles | COVID-19 and SARS-CoV-2: Vaccines and Drug Development

Journal of Bioprocessing & Biotechniques

ISSN: 2155-9821

Open Access

Special Issue: COVID-19 and SARS-CoV-2: Vaccines and Drug Development

SARS-CoV2 is a novel coronavirus identified as the cause of coronavirus disease 2019 (COVID-19) that began in Wuhan, China in late 2019 and spread worldwide.

Treatment of COVID-19 is supportive. No vaccine, antiviral drug, or other specific treatment is available. Over 175 treatment and vaccine clinical trials are currently registered, but data on effective therapy remains sparse. Current therapeutic strategies in practice for severe disease include antiviral agents (notably remdesivir, in clinical trial), chloroquine derivatives, and immunomodulatory agents, namely Il-6 inhibitors such as tocilizumab.

The Upcoming Special Issue will focus on the recent research going on for the Drug Development and possible Vaccines that could control the widespread infection of Novel Corona Virus.

Submission Process Special issue articles can include both original unpublished research articles and review articles related to the specific theme. Manuscripts will be accepted for publishing in the special issue only after getting approved by the peer review committee [selected by the guest editor(s)]. All the articles in special issues should strictly adhere to journal style and formatting. Each special issue can be created with 10-15 articles. All accepted manuscripts can be submitted online at

For further information on special issue guidelines and submission process, please contact [email protected]

Google scholar citation report
Citations: 2325

Journal of Bioprocessing & Biotechniques received 2325 citations as per google scholar report

Journal of Bioprocessing & Biotechniques peer review process verified at publons

Indexed In

arrow_upward arrow_upward